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Abstract
Background and Objective Oral levodopa-carbidopa
(LC-oral) treatment in advanced Parkinson’s disease (PD)
is associated with motor complications due to large fluc-
tuations in levodopa plasma concentrations. Levodopa–
carbidopa intestinal gel (LCIG) provides individualized
continuous levodopa–carbidopa delivery through intraje-
junal infusion. This study evaluated the pharmacokinetics,
safety, and efficacy of LCIG relative to LC-oral in Ja-
panese subjects with advanced PD.
Methods Subjects with advanced PD were converted from
their anti-PD medications to individually optimized doses of
LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (base-
line; period 1) followed by switching to intrajejunal infusion
of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics,
adverse events (AEs), and efficacy were assessed.
Results Eight patients were enrolled. Six received LCIG
and four reported at least one AE [most common: fall
(33.3 %), dyskinesia (33.3 %)]; one discontinued due to an
AE. The average daily dose was 1230/123 and 1370/342 mg
levodopa/carbidopa for LC-oral and LCIG, respectively, at
the end of each period. The degree of fluctuation and intra-
subject variability of levodopa plasma concentrations were
5.5- and 4-fold lower, respectively, with LCIG than with LC-
oral. Levodopa bioavailability was 99 % for LCIG relative to
LC-oral. Compared with baseline, LCIG decreased ‘‘Off’’
time (2.68 h, P = 0.002) and increased ‘‘On’’ time without
troublesome dyskinesia (2.35 h, P = 0.006) in the PD
Diary. With the small sample size, no statistically sig-
nificant changes were seen on other efficacy endpoints.
Conclusions In Japanese subjects with advanced PD,
LCIG resulted in an improved pharmacokinetic profile that
appeared to be associated with reduced motor complica-
tions compared with LC-oral. These results extend previ-
ous findings in mainly Caucasian populations.
Key Points
Continuous jejunal infusion of levodopa–carbidopa
intestinal gel (LCIG) provides a viable option to
patients with advanced Parkinson’s disease (PD)
who experience motor complications that are
inadequately controlled by standard oral therapy.
Pharmacokinetic and efficacy benefits of continuous
jejunal infusion of LCIG have been previously
demonstrated in Western patients.
This study demonstrates that LCIG jejunal infusion
results in lower fluctuations in levodopa
concentrations and shows comparable bioavailability
to oral administration in Japanese subjects with
advanced PD. The improved pharmacokinetic profile
with LCIG infusion appears to be associated with
reduced motor complications.
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1 Introduction
Levodopa is the gold-standard treatment of Parkinson’s
disease (PD) and is eventually used by all PD patients [1].
However, the majority of PD patients who receive levodopa
for 5–10 years develop disabling motor complications
(motor fluctuations and dyskinesias) [2]. Development of
motor complications is attributed to the narrowing of the
therapeutic window between brain dopamine concentra-
tions that precipitate abnormal involuntary movements
(dyskinesias) and those that ameliorate the parkinsonian
symptoms as the disease progresses [3, 4]. Maintaining
levodopa plasma concentrations, and consequently brain
dopamine concentrations, within a patient-specific narrow
therapeutic window is challenging. Intermittent frequent
administration of standard oral levodopa formulations leads
to fluctuating plasma concentrations due erratic gastric
emptying and the short half-life of levodopa [5–9].
Levodopa–carbidopa intestinal gel (LCIG; Duodopa;
Duopa; AbbVie, North Chicago, IL, USA) is a suspension
of levodopa and carbidopa (20 and 5 mg/mL, respectively)
in an aqueous sodium carboxymethylcellulose gel. LCIG is
infused through a portable pump (CADD-Legacy, Smith
Medical, Minneapolis, MN, USA) directly into the jejunum
via a nasojejunal (NJ) (short-term) or percutaneous gas-
trojejunostomy tube (long-term therapy) [10]. In the je-
junum, levodopa is rapidly absorbed by an active carrier
mechanism localized in the proximal small intestine [11].
By providing consistent levodopa plasma concentrations
with patient-specific dosing, LCIG provides individualized
continuous, rather than intermittent, stimulation of the
dopaminergic receptors in the brain [3, 12]. LCIG has been
shown to reduce the motor fluctuations, increase the ‘On’
time and decreased the incidence of dyskinesia in patients
with advanced PD who have previously received oral
treatment with levodopa for many years [13–16].
LCIG is approved for clinical use in more than 40 countries
and is currently being studied in Japanese subjects. This was
the first dedicated study to evaluate LCIG (4:1 levodopa:-
carbidopa ratio) relative to oral levodopa–carbidopa tablets
(LC-oral, 10:1 levodopa:carbidopa ratio as approved in Ja-
pan) in Japanese subjects with advanced PD. The study was
conducted in preparation for the Japan phase III clinical trial.
Previous clinical trials of LCIG evaluated subjects of mainly
(95–100 %) Caucasian ethnicity and compared LCIG with
oral 4:1 levodopa:carbidopa tablets [3, 12, 14].
2 Methods
This study was an open-label, single-arm, baseline-con-
trolled, multicenter study in subjects with advanced PD
with severe motor complications despite optimized oral
treatment with anti-PD medications. The study was de-
signed to assess the pharmacokinetics, safety, and efficacy
of LCIG relative to baseline treatment with LC-oral. Adult
subjects (aged C30 years) were eligible to participate in the
study if they met the following criteria: a diagnosis of id-
iopathic PD according to the United Kingdom Parkinson’s
Disease Society (UKPDS) Brain Bank criteria, with their
disease stage corresponding to 4 or 5 in the ‘‘Off’’ state
(according to the modified Hoehn and Yahr classification)
and which could not be satisfactorily controlled with opti-
mized medical therapy; responsive to treatment with oral
levodopa; severe motor fluctuations and dyskinesia; and a
minimum daily ‘‘Off’’ time of 3 h during a continuous 16-h
interval as supported by the subject PD diaries for 3 con-
secutive days including the portion of the day during which
the subject was awake for the majority of the time (e.g.,
6 a.m. to 10 p.m.). Additional inclusion criteria included
being able to discontinue previous anti-PD medications
other than the study drugs throughout the study and to keep
a PD Diary [17] of ‘‘Off’’ time and dyskinesia.
Exclusion criteria included unclear diagnosis of PD,
suspected diagnosis of other parkinsonian syndromes; other
neurodegenerative diseases; history of neurosurgery for the
treatment of PD or any other brain surgery; any neuro-
logical deficit that could possibly interfere with the study
assessments; known hypersensitivity to levodopa, car-
bidopa, or any other constituent of LCIG or LC-oral
tablets, or radiopaque material; concomitant narrow-angle
glaucoma; a history of pheochromocytoma, Cushing’s
syndrome or malignant melanoma; having contraindica-
tions for the placement of an NJ tube; or any medical,
surgical, and/or laboratory issues deemed by the investi-
gator to be clinically significant.
The study [18] was conducted in five sites in Japan
(National Center of Neurology and Psychiatry, Tokyo;
Ehime University Hospital, Ehime; Wakayama Medical
University Hospital, Wakayama; Juntendo University
Hospital, Tokyo; and National Hospital Organization
Utano Hospital, Kyoto). The study protocol and informed
consent were approved by the institutional review board at
each participating site.
2.1 Study Procedures
The study consisted of a screening period (maximum
14 days), a run-in period (28 days), an LCIG treatment
period (21 days), and a follow-up period (7 days), as
shown in Fig. 1. Subjects were hospitalized during the last
2 days of the run-in period (Days -2 and -1) and during
the entire LCIG treatment period. The remainder of the
study period was conducted under outpatient conditions.
During the run-in period, subjects were switched from
their prior anti-PD medications to monotherapy with the
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LC-oral tablets (levodopa 100 mg and carbidopa 10 mg;
Menesit, Merck Sharp & Dohme, Tokyo, Japan) and
optimized on a six times daily schedule (every third hour;
e.g., 6 a.m., 9 a.m., 12 p.m., 3 p.m., 6 p.m., 9 p.m.) during
waking hours. The method for switching prior anti-PD
medications to monotherapy with the LC-oral tablet was
determined by the investigator based on the package insert
of anti-PD medications and the LC-oral tablets. The run-in
period was to allow the stabilization of PD symptoms
following the elimination of previous long-acting anti-PD
medications. Subjects used the PD and dosing diaries for 3
consecutive days prior to being hospitalized on Day -2.
Subjects were trained on the appropriate use of the PD
Diary during the screening period and the concordance
rate between the subject’s and investigator’s assessment
had to be at least 75 % for the subject to enter the run-in
period. All medications taken by the subject during the
study [from signing the informed consent form until fol-
low-up (Day ?7)] were recorded.
On the baseline assessment day (Day -1; last day in the
run-in period), subjects were recorded on video equipment
for 1–2 min while performing a series of assigned move-
ments (rest, finger taps, rapid alternating movement of
hands, arising from chair and gait; including confirmation
of postural stability) every 60 min from 8 a.m. to 5 p.m.
Blood samples for pharmacokinetic analysis were collect-
ed. Subjects fasted overnight from the day before the
baseline assessment day (Day -2). Water was allowed
ad libitum. Subjects were requested not to consume ex-
cessive amounts of caffeine or caffeine-containing
products per day and alcoholic beverages from 48 h prior
to and throughout the confinement period. During the
daytime, normal meals were allowed. Subjects were in-
structed to refrain from making any significant dietary
changes throughout the duration of the study as a high-
protein diet may reduce the effectiveness of levodopa ad-
ministration independent of the mode of delivery.
An NJ tube was inserted in the morning of the first day
of the LCIG treatment period (Day 1). Treatment with
LCIG via the infusion pump was initiated after ra-
diologically confirming the NJ tube tip location in the
proximal jejunum. On Day 20, tube placement was
checked, and if there was any indication that the tube was
displaced, it was repositioned to the correct position.
LCIG was administered with an infusion pump via the
NJ tube for 16 h a day (waking hours) directly into the
proximal jejunum. Delivery of LCIG was via an aqueous
suspension of levodopa (20 mg/mL) and carbidopa
monohydrate (5 mg/mL) in 100 mL cassettes. LCIG was
administered as a morning bolus (5–10 mL) followed by
continuous infusion at a constant rate for the remainder of
each patient’s waking day (16 h), and, if needed, inter-
mittent extra doses (patient initiated based on symptoms
experience). The infusion was stopped overnight. The dose
of LCIG on the first day of the LCIG treatment period
(Day 1) was based on the daily dose of the oral levodopa
component from the LC-oral tablets taken at baseline
(Day -1). Dosing was optimized during the first 3–7 days
of LCIG treatment to maximize the functional ‘‘On’’ time
during the day by minimizing the number of ‘‘Off’’
Fig. 1 Study design. LCIG levodopa–carbidopa intestinal gel, Max maximum, NJ nasojejunal, PK pharmacokinetics
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(bradykinesia) episodes, the ‘‘Off’’ time, and the ‘‘On’’
time with troublesome dyskinesia. LCIG dose readjust-
ments and patient-initiated extra doses were allowed except
for on the last day of the LCIG treatment period (Day 21).
On Day 21, subjects were recorded on video equipment
in the same manner as at baseline and blood samples for
pharmacokinetic analysis were collected. Subjects fasted
overnight (e.g., starting from 10 p.m. on the previous day)
and dietary guidelines on Day 21 were similar to Day -1.
At the end of the LCIG treatment period, the NJ tube was
removed after completion of all assessments required and
the subjects were discharged from the hospital. Subjects
were permitted, if necessary, to self-administer their typical
night-time dosage of LC-oral tablets during the run-in and
LCIG periods. However, no night-time intake of the LC-
oral tablet was allowed at least 3 h before the morning
dosing of LC-oral or LCIG on the morning of the video
recording day.
2.2 Blood Sampling and Pharmacokinetic Analysis
Blood samples (4 mL each) for pharmacokinetic analysis
were collected at baseline (Day -1; last day of the run-in
period) and end of LCIG treatment (Day 21). On Day -1,
blood samples were collected at time 0 and at 15, 30, 45,
and 60 min following the morning dose and every 30 min
thereafter for 12 h. On Day 21, blood samples were col-
lected at the same timepoints as for Day -1 and every 2 h
from hours 12 to 16 relative to the start of the infusion.
Plasma concentrations of levodopa, carbidopa, and 3-O-
methyldopa were determined by liquid chromatography
with tandem mass spectrometry (LC-MS/MS) as previ-
ously described [3]. The analytical assay was validated
over the concentration ranges of 10–5000, 0.5–250, and
25–25,000 ng/mL for levodopa, carbidopa, and 3-O-
methyldopa, respectively. In-study between-run variability
[% coefficient of variation (%CV)] was B9.8 % and the
mean absolute bias was B5.2 % for all three analytes.
Pharmacokinetic parameters for levodopa, carbidopa,
and 3-O-methyldopa were estimated using non-compart-
mental methods. These included the maximum observed
plasma concentration (Cmax), time to Cmax (tmax), the
minimum observed plasma concentration (Cmin), area un-
der the plasma concentration–time curve (AUC), and the
average plasma concentrations (Cavg). Pharmacokinetic
parameters were calculated for 12-h intervals relative to
administration of the first morning LC-oral dose on Day
-1 and for 12- and 16-h intervals relative to the start of the
LCIG infusion on Day 21. Additionally, Cmax, Cmin, and
Cavg values were calculated for the 2- to 12-h and 2- to
16-h intervals as applicable.
The degree of fluctuation for the 2- to 12-h interval
relative to administration of first morning LC-oral dose
and for the 2- to 12- and 2- to 16-h intervals relative
to the start of the LCIG infusion were determined as
(Cmax–Cmin)/Cavg using the parameters calculated for the
corresponding intervals. The 3-O-methyldopa to levodopa
AUC from time zero to 12 h (AUC12) ratios were cal-
culated. The inter- and intra-subject coefficient of varia-
tion for plasma concentrations were estimated for the
2- to 12-h intervals on Days -1 and 21 and for the 2- to
16-h interval on Day 21 using a linear mixed–effects
model for log concentrations, with fixed effects for time
and random effects for subject and occasion within sub-
ject. Levodopa bioavailability from LCIG compared to
LC-oral was estimated by non-linear mixed–effects
modeling with NONMEM (version 7.3; Icon Develop-
ment Solutions, Ellicott City, MD, USA) using a previ-
ously published model for levodopa with both methods of
administration [19].
2.3 Efficacy Assessment
Efficacy was assessed using the Treatment Response Scale
(TRS) [13] calculated based on evaluation of video
recordings made every 60 min from 8 a.m. to 5 p.m. on
Day -1 (end of run-in LC-oral treatment period) and Day
21 (end of LCIG treatment period) by blinded raters
(trained neurologists). Subjects were recorded on video
equipment a total of ten times for 1–2 min every 60 min
while performing a standardized sequence of motor tasks.
As a blinded method for video evaluation, a dummy NJ
tube was attached to the subject during video recording at
the end of the LC-oral treatment (Day -1) and video
recordings for each subject were provided to the raters in a
random order. The three neurologists individually
evaluated the video recordings. TRS I was calculated based
on evaluation of the finger taps, rapid alternating move-
ment of hands, arising from chair, gait, body bradykinesia
and hypokinesia, and dyskinesia. Evaluation grades for
TRS I were -3, ‘‘severe Off’’; -2, ‘‘moderate Off’’; -1,
‘‘mild Off’’; 0, ‘‘On without dyskinesia’’; and ?1, ‘‘On
with mild dyskinesia’’. The percentage of ratings in the
range of -1 to ?1 (‘‘mild Off’’ to ‘‘On with mild
dyskinesia’’) on the TRS I at the end of the LCIG treatment
period (Day 21) compared with that of administration of
LC-oral tablets at baseline (Day -1) was determined. Inter-
rater reliability for TRS I was assessed by calculating a
Kraemer j coefficient. A comparison of the efficacy be-
tween the end of the LCIG treatment period and baseline
was carried out using a paired t test at a two-sided sig-
nificance level of 5 %. Other efficacy parameters included
the mean daily ‘‘Off’’ time (h), the mean daily ‘‘On time
with troublesome dyskinesia’’ and the mean daily ‘‘On time
without troublesome dyskinesia’’ on the PD Diary during
3 consecutive days (i.e., Days 18–20) prior to the end of the
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LCIG treatment period (Day 21) and during 3 consecutive
days (i.e., Days -5 to -3) prior to baseline (Day -1).
2.4 Safety
All adverse events (AEs) reported from the first day of the
run-in period until 30 days following completion or dis-
continuation of study drug administration were collected.
Safety assessments included physical examination, neuro-
logical examination, vital signs, single ECG, blood sam-
pling for clinical laboratories, hematology, blood
chemistry, urinalysis, and scatoscopy.
The safety analysis included all subjects who had at
least one dose of LC-oral study medication administered
during the run-in period. LCIG safety analysis included all
subjects who had had at least one dose of the LCIG study
medication after the baseline assessment.
2.5 Determination of Sample Size
The sample size was estimated based on a previous open-
label, crossover study, which suggested that five subjects
were required to have 80 % power to detect a mean change
of 14 % in the percentage of ratings in the interval –1 to
?1 on the TRS I at a two-sided a-level of 0.05 [12]. Since
this study was the first study of LCIG conducted in Japan
and required subjects to receive LCIG via an NJ tube for a
relatively longer period, the target number of subjects to be
included in this study was eight, assuming a higher dropout
rate (30 %) than previously seen.
3 Results
3.1 Subjects’ Disposition
A total of eight (six male and two female) Japanese sub-
jects with advanced PD (mean age of 65.4 years, range
58–72 years; mean bodyweight of 53.9 kg, range
42.0–66.0 kg; mean body mass index of 20.8 kg/m2, range
17.5–23.9 kg/m2; and mean disease duration of 14.9 years,
range 7.8–19.9 years) were enrolled in the study.
Two subjects prematurely discontinued the study in the
run–in period [one subject did not meet the inclusion cri-
teria at the beginning of the LCIG period and the other
subject discontinued due to AEs (non-serious, probably not
related) and withdrawal of informed consent] and six
subjects were treated with LCIG. Out of the six subjects,
one subject prematurely discontinued the study due to AEs
(somatic hallucination, delusion, and auditory hallucina-
tion) in the LCIG treatment period and five subjects com-
pleted the study. In one subject, NJ tube was found to be
displaced on Day 20, which was one of the three PD
Diary evaluation days. The tube was repositioned and the
subject was included in pharmacokinetic, safety, and effi-
cacy analyses, but was excluded from the PD Diary
evaluation.
3.2 Pharmacokinetic Results
The pharmacokinetic parameters for levodopa, carbidopa,
and levodopa’s metabolite 3-O-methyldopa are summa-
rized in Table 1. Inter- and intra-subject variability (%CV)
Table 1 Pharmacokinetic parameters (mean ± standard deviation) of levodopa, carbidopa, and 3-O-methyldopa after administration of oral
levodopa–carbidopa (10:1 levodopa:carbidopa ratio) tablets and jejunal infusion of levodopa–carbidopa intestinal gel (4:1 levodopa:carbidopa
ratio) in Japanese subjects with advanced Parkinson’s disease
Pharmacokinetic parameters LC-oral tablets (n = 5) LCIG infusion (n = 5)
Levodopa Carbidopa 3-O-methyldopa Levodopa Carbidopa 3-O-methyldopa
Total study drug daily dosea (mg) 1230 ± 246 123 ± 25 1370 ± 353 342 ± 88
tmax (h) 3.0 ± 3.5 7.8 ± 2.8 11 ± 0.76 1.0 ± 0.50 4.5 ± 4.2 11 ± 0.79
Cmax (lg/mL) 5.96 ± 0.768 0.128 ± 0.025 9.27 ± 2.17 4.38 ± 1.15 0.273 ± 0.066 11.7 ± 1.25
Cavg (lg/mL) 2.37 ± 0.257 0.079 ± 0.015 7.36 ± 1.93 2.87 ± 0.663 0.172 ± 0.044 9.80 ± 1.23
AUC12 (lgh/mL) 28.4 ± 3.08 0.943 ± 0.177 88.3 ± 23.1 34.4 ± 7.95 2.07 ± 0.522 118 ± 14.7
AUC16 (lgh/mL) 46.7 ± 10.7 2.80 ± 0.666 165 ± 21.2
Cmin (2–12 h) (lg/mL) 0.734 ± 0.425 0.050 ± 0.017 5.72 ± 1.53 2.38 ± 0.770 0.130 ± 0.035 8.14 ± 0.936
Degree of fluctuation (2–12 h)b 2.1 ± 0.59 0.97 ± 0.20 0.48 ± 0.10 0.38 ± 0.16 0.78 ± 0.25 0.35 ± 0.07
M/P (AUC12) 3.11 ± 0.71 3.53 ± 0.70
AUCx area under the plasma concentration–time curve from time zero to x h, Cavg average plasma concentration, Cmax maximum observed
plasma concentration, Cmin minimum observed plasma concentration, LCIG levodopa–carbidopa intestinal gel, LC-oral oral levodopa–carbidopa,
M/P ratio of metabolite (3-O-methyldopa) to parent (levodopa), tmax time to Cmax
a Total dose between hours 0 and 16 on the day of pharmacokinetic assessment (Day -1 for LC-oral tablets, Day 21 for LCIG)
b Degree of fluctuation calculated as (Cmax–Cmin)/Cavg
LCIG in Japanese Subjects with Advanced Parkinson’s Disease 979
for levodopa, carbidopa, and 3-O-methyldopa plasma
concentrations during Hours 2–12 following administration
of the first morning LC-oral tablet or initiation of LCIG
intrajejunal infusion are presented in Table 2. Levodopa
and carbidopa plasma concentrations [mean ± standard
deviation (SD)] versus time profiles after administration of
LC-oral tablets and intrajejunal infusion of LCIG in Ja-
panese subjects with advanced PD are presented in Fig. 2.
The average daily dose on the pharmacokinetic assess-
ment day was 1230/123 and 1370/342 mg levodopa/car-
bidopa for LC-oral and LCIG, respectively. Levodopa and
carbidopa mean Cavg values were 2.37 and 0.079 lg/mL
for LC-oral and 2.87 and 0.172 lg/mL for LCIG, respec-
tively. Degree of fluctuation and intra-subject variability in
levodopa plasma concentrations were 5.5- and 4-fold
lower, respectively, with LCIG than with LC-oral admin-
istration. LCIG resulted in approximately 2.2-fold higher
exposure of carbidopa than administration of LC-oral
tablets, which is consistent with the difference in the car-
bidopa dose in the two products. Following infusion ter-
mination on the night prior to LCIG pharmacokinetic
assessment, none of the subjects received night-time doses
of LC-oral tablets.
Using a previously developed pharmacokinetic model of
levodopa with LCIG and LC-oral administration, levodopa
bioavailability from intrajejunal infusion of LCIG relative
to that with administration of LC-oral tablets was estimated
to be 99.2 % (95 % CI 96.5–102).
The pharmacokinetic parameters of levodopa, car-
bidopa, and 3-O-methyldopa after intrajejunal infusion of
LCIG in Japanese subjects (current study) compared with
previous observations in Caucasian subjects [3] are pre-
sented in Table 3. Comparison of levodopa and carbidopa
plasma concentrations (mean and SD) versus time profile
after intrajejunal infusion of LCIG in Japanese (current
study) and Caucasian subjects [3] with advanced PD are
presented in Fig. 3. The average daily levodopa/carbidopa
LCIG dose in the Caucasian study was 1580/395 mg
compared with 1370/ 342 mg in the present study.
3.3 Efficacy
A summary of the efficacy assessments using the TRS I
video recordings and the PD Diary is presented in
Table 4.
The mean increase (improvement) in the ‘‘normal’’ state
on TRS I by video assessment from LC-oral baseline to the
end of LCIG treatment was numerically favorable but did
not reach statistical significance. The Kraemer j coefficient
for concordance between the three raters on TRS I was
0.22.
PD Diary results show that the mean change in the
‘‘Off’’ time from baseline to the end of LCIG treatment was
reduction of 2.68 h (95 % CI -3.51 to -1.84, P = 0.002).
The mean increase in the ‘‘On’’ time without dyskinesia
plus time with non-troublesome dyskinesia from baseline
to the end of LCIG treatment was 2.35 h (95 % CI
1.28–3.43, P = 0.006). Other evaluated efficacy measures
did not reach statistical significance.
3.4 Safety and Tolerability
The most frequently reported AEs in the run-in period (LC-
oral) were constipation and insomnia (three subjects each,
37.5 %), and nausea (two subjects, 25.0 %), and those in
the LCIG treatment period were fall and dyskinesia (two
subjects each, 33.3 %). The AEs reported in the study are
common conditions associated with PD or are known AEs
associated with LC-oral. Three AEs (thirst, nausea, and
decreased appetite) occurred in one subject and were all
assessed by the investigator as probably related to both
study drug and NJ tube insertion.
4 Discussion
This open-label, single-arm, baseline-controlled, multi-
center study evaluated the pharmacokinetics, safety, and
efficacy of continuous intrajejunal infusion of LCIG
(Duodopa) in Japanese subjects with advanced PD. The
study suggests that Japanese subjects with advanced PD
can be safely converted from LC-oral (10:1 levodopa:car-
bidopa ratio) to LCIG (4:1 levodopa:carbidopa ratio). On
the pharmacokinetic assessment day, consistent plasma
concentrations of levodopa were achieved shortly after
starting the daily intrajejunal infusion of LCIG and these
consistent concentrations were maintained through the
Table 2 Inter- and intra-subject variability (% coefficient of varia-
tion) for levodopa, carbidopa, and 3-O-methyldopa plasma concen-
trations during hours 2–12 following administration of the first
morning oral levodopa–carbidopa tablet or initiation of levodopa–
carbidopa intestinal gel infusion






Levodopa 5 19 24 38 10
Carbidopa 5 20 24 29 20
3-O-
methyldopa
5 26 13 7 7
Estimates based on a linear mixed–effects model for log concentra-
tion with fixed effects for time and random effects for subject and for
occasion within subject
CV coefficient of variation, LCIG levodopa–carbidopa intestinal gel,
LC-oral oral levodopa–carbidopa
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daily infusion period (Fig. 2). Intra-subject variability in
levodopa plasma concentrations was low (10 %) during
LCIG treatment compared with LC-oral (38 %; Table 2),
and LCIG infusion displayed more than five-fold decrease
in the degree of fluctuation in levodopa plasma concen-
trations compared with LC-oral (Table 1). The high fluc-
tuations in levodopa concentrations with LC-oral treatment
are attributed to levodopa’s short half-life (approximately
1.5 h) [20] coupled with its erratic gastric emptying and
site-specific intestinal absorption. These limitations are
addressed by continuous intrajejunal delivery of LCIG.
This improved pharmacokinetic profile with LCIG intra-
jejunal infusion appeared to translate to better control of
motor symptoms (Table 4).
Ethnic differences have been suggested in the response
to levodopa–carbidopa therapy, and therefore in oral
dosing requirements. Asian patients with PD appear to
require 20–30 % lower doses of oral levodopa to control
their symptoms and appear to develop dyskinesias more
frequently than Caucasians [21, 22]. This can be a result of
higher levodopa bioavailability or greater pharmacody-
namic sensitivity in Japanese subjects. We have previously
characterized the pharmacokinetic profile of LCIG in
Caucasian subjects with advanced PD [3]. The average
daily levodopa/carbidopa LCIG dose in the Caucasian
study was 1580/395 mg compared to 1370/342 mg in the
present study. Intrajejunal infusion of individualized doses
of LCIG in Japanese and Caucasian subjects resulted in
comparably low fluctuations in levodopa concentrations
and in superimposable mean levodopa plasma concentra-
tions (Fig. 3; Table 3). The dose-normalized levodopa
AUC during the 16-h infusion appeared to be 17 % higher
Fig. 2 Levodopa and carbidopa plasma concentrations (mean ± standard deviation) versus time profiles after administration of oral levodopa–
carbidopa tablets (10:1 levodopa:carbidopa ratio; a, c) and intrajejunal infusion of levodopa–carbidopa intestinal gel (4:1 levodopa:carbidopa
ratio; b, d) in Japanese subjects with advanced Parkinson’s disease (n = 5). LCIG levodopa–carbidopa intestinal gel
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in Japanese subjects than previously observed in Caucasian
subjects. Japanese subjects who participated in this study
had lighter bodyweight, on average, compared with the
Caucasian subjects evaluated in the previous study (54 vs.
66 kg average bodyweight). In the population pharma-
cokinetic analysis of levodopa data from Western LCIG
Phase I and III studies (bodyweight range of 45–148 kg),
we previously assessed bodyweight as a covariate for
levodopa pharmacokinetic parameters and bodyweight was
not found to be significantly correlated to levodopa clear-
ance (which determines levodopa AUC; rather, bodyweight
was better correlated with the levodopa volume of distri-
bution) [19]. Findings from other levodopa population
analyses were inconsistent regarding the contribution of
bodyweight in explaining inter-subject variability in levo-
dopa clearance, as previously discussed [19]. Overall, the
small difference in levodopa dose-normalized AUC be-
tween the Japanese and Caucasian populations, if real, has
no clinical relevance for LCIG since doses are individually
titrated in each patient for optimal symptom control.
Carbidopa exposure in Japanese subjects appeared to be
lower than in Caucasian subjects (Table 3), mainly because
of lower carry-over carbidopa plasma concentrations
(Fig. 3b). This is consistent with the lack of use of night-
time LC-oral tablets by Japanese patients in the current
study, while most Caucasian patients in the previous study
used night-time LC-oral tablets after discontinuation of the
LCIG infusion on the night prior to the pharmacokinetic
assessment day. Carbidopa reduces peripheral decarboxy-
lation of levodopa to dopamine (which does not cross the
blood–brain barrier) and directs more levodopa metabolism
towards the catechol-O-methyl transferase (COMT) en-
zyme pathway (which generates the inactive metabolite,
Table 3 Comparison of the pharmacokinetic parameters (mean ± SD) of levodopa, carbidopa, and 3-O-methyldopa after intrajejunal infusion
of levodopa–carbidopa intestinal gel in Japanese subjects (current study) and Caucasian subjects [3]
Pharmacokinetic parametersa Japanese subjects (n = 5) Caucasian subjects (n = 18)
Levodopa Carbidopa 3-O-methyldopa Levodopa Carbidopa 3-O-methyldopa
Total study drug daily doseb (mg) 1370 ± 353 342 ± 88 1580 ± 403 395 ± 101
Cmax (lg/mL) 4.38 ± 1.15 0.284 ± 0.047 12.9 ± 2.26 4.21 ± 1.36 0.371 ± 0.149 19.0 ± 5.66
Cavg (lg/mL) 2.92 ± 0.666 0.175 ± 0.042 10.3 ± 1.33 2.91 ± 0.836 0.221 ± 0.083 17.1 ± 4.99
Cmin (lg/mL) 0.061 ± 0.027 0.016 ± 0.005 7.78 ± 0.632 0.447 ± 0.282 0.103 ± 0.067 15.1 ± 4.85
AUC16 (lgh/mL) 46.7 ± 10.7 2.80 ± 0.666 165 ± 21.2 46.5 ± 13.3 3.54 ± 1.33 273 ± 79.8
Cmin (2–16 h) (lg/mL) 2.38 ± 0.77 0.128 ± 0.034 8.14 ± 0.936 2.32 ± 0.583 0.167 ± 0.073 15.4 ± 4.72
Degree of fluctuationc (2–16 h) 0.42 ± 0.16 0.87 ± 0.19 0.44 ± 0.11 0.52 ± 0.20 0.96 ± 0.49 0.21 ± 0.11
M/P (AUC16) 3.64 ± 0.69 5.97 ± 1.09
AUC16 area under the plasma concentration–time curve from time zero to 16 h, Cavg average plasma concentration, Cmax maximum observed
plasma concentration, Cmin minimum observed plasma concentration, M/P ratio of metabolite (3-O-methyldopa) to parent (levodopa)
a Parameters are for 0–16 h infusion interval unless otherwise specified
b Total dose between hours 0 and 16 on the day of pharmacokinetic assessment
c Degree of fluctuation calculated as (Cmax–Cmin)/Cavg
Fig. 3 Comparison of levodopa and carbidopa plasma concentrations
(mean ± standard deviation) versus time profiles after 16-h intraje-
junal infusion of LCIG in Japanese (a; n = 5) and Caucasian (b;
n = 18) subjects with advanced Parkinson’s disease. Data for
Caucasian subjects were previously reported [3]
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3-O-methyldopa). Exposure of 3-O-methyldopa was lower
in Japanese subjects than in Caucasians (Table 3), which
may be partially explained by the lower carbidopa plasma
concentrations in Japanese subjects. Given the similarity
across populations in plasma concentrations of the active
moiety (levodopa) that mediates efficacy, the observed
differences in carbidopa or 3-O-methyldopa exposure be-
tween populations are not clinically relevant.
Rivera-Calimlim and Reilly [22] suggested higher ac-
tivity of the COMT enzyme in Japanese subjects. The 3-O-
methyldopa exposure levels with LCIG use (same levo-
dopa–carbidopa dose ratio across populations) are not
supportive of higher COMT activity in Japanese subjects.
In the present study, the bioavailability of levodopa
from LCIG relative to LC-oral tablets is estimated to be
99.2 %. This is consistent with levodopa’s bioavailability
estimate (97 %) for LCIG relative to LC-oral from a pre-
vious population pharmacokinetic analysis in mainly
Caucasian subjects [19].
The potential benefit of the improved pharmacokinetic
profile of levodopa with LCIG infusion was evaluated. A
trend of improvement was observed in the percentage of
subjects in the ‘‘normal’’ state on the TRS I video
assessment, which did not reach statistical significance
(Table 4). Lack of statistical significance is likely a result
of the small sample size, the high inter-rater variability
(Kraemer j coefficient for concordance between the three
raters on TRS I was 0.22), and, potentially, the short
evaluation duration (2 min) within each of the assessment
hours. Statistically significant improvements in ‘‘Off’’
time and ‘‘On’’ time without troublesome dyskinesia in
the PD Diary evaluation were observed. The latter
analysis excluded one subject for whom the NJ tube was
dislocated (not in jejunum) on one of the PD Diary
evaluation days.
The most frequently reported AEs in the LCIG treatment
period were fall and dyskinesia, which are common con-
ditions associated with Parkinson’s disease or are known
AEs associated with LC-oral. The majority of the AEs were
assessed as mild or moderate in severity and were observed
to decline over time. The safety assessment in this study is
limited by the small number of subjects assessed during
LCIG treatment (six subjects). While this number is suffi-
cient to evaluate common AEs (C30 %), it may have not
been sufficient to identify less common ones. Additionally,
LCIG was infused in this study through an NJ tube due to
the exploratory nature of the study and the relatively short
duration. However, in clinical practice, LCIG is infused
through a percutaneous gastrojejunostomy tube inserted by
a surgical procedure. In a recent relatively large random-
ized controlled, double-blind, double-dummy study of
LCIG compared with LC-oral in a Western population, the
majority of reported AEs during LCIG treatment were re-
lated to the surgical procedure or the intestinal tube [14].
Overall, this study suggests that Japanese subjects with
advanced PD can be safely converted from LC-oral (10:1
ratio) to LCIG (4:1 ratio). LCIG intrajejunal infusion re-
sults in lower fluctuations in levodopa concentrations and
comparable bioavailability as that of oral administration in
Japanese subjects with advanced PD. The improved phar-
macokinetic profile with LCIG infusion appeared to be
associated with reduced motor complications. These results
extend previous findings in mainly Caucasian populations.
Based on the results from this study, a phase III study of
Table 4 Efficacy of levodopa–carbidopa intestinal gel (endpoint) relative to oral levodopa–carbidopa (baseline) using the ‘‘normal’’ state on
Treatment Response Scale (TRS) I (video assessment) and the Parkinson’s Disease Diary assessment









treatments) [mean ± SD]





TRS I (%) ‘‘normal’’ stateb 5 62.7 ± 18.2 78.0 ± 8.69 15.3 ± 14.26 -2.37, 33.0 0.074
Parkinson’s Disease Diary assessmentc
Daily ‘‘Off’’ time (h) 4 7.51 ± 2.75 4.83 ± 2.51 -2.68 ± 0.52 -3.51, -1.84 0.002
Daily ‘‘On’’ time without
dyskinesia ? time with non-
troublesome dyskinesia (h)
4 7.74 ± 1.48 10.1 ± 1.57 2.35 ± 0.68 1.28, 3.43 0.006
Daily ‘‘On’’ time with
troublesome dyskinesia (h)
4 0.75 ± 1.5 1.08 ± 1.6 0.33 ± 0.5 –0.43, 1.08 0.261
a P value: paired t test
b ‘‘Normal’’ state: internal –1 to ?1 (‘‘mild Off’’ to ‘‘On with mild dyskinesia’’)
c One subject was excluded from the Parkinson’s Disease Diary assessment due to non-compliance (displacement of the nasojejunal tube) on
an assessment day (Day 20)
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LCIG in Japanese subjects was initiated and is currently
ongoing (NCT01960842) [23].
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